Coronavirus Vaccines As A Public Good: How Reasonable Is Reasonable?
Chinese Official Says They Must Be 'Affordable'
Executive Summary
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
You may also be interested in...
Rapid Response, No Ultracold: China Sees Global Opening For Vaccine Supplies
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.